Status:
COMPLETED
Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular
Lead Sponsor:
The Cleveland Clinic
Conditions:
Neuromuscular Blockade
Anesthesia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The aim of this study is to evaluate whether the use of Sugammadex for reversing the neuromuscular blocking effects of rocuronium during neurointerventional procedures can speed recovery of neuromuscu...
Detailed Description
Incomplete recovery from neuromuscular blocking agents (NMBAs) residual block after anesthesia and surgery continues to be a common problem in the postanesthesia care (PACU). Neostigmine remains the ...
Eligibility Criteria
Inclusion
- Age ≥ 18 years;
- American Society of Anesthesiologists (ASA) physical status 1-3;
- Scheduled for catheter-based neurointerventional procedures including coiling and stent insertion;
- General anesthesia.
Exclusion
- Suspected difficult intubation;
- Neuromuscular disorder;
- Renal impairment creatinine ≥ 2 mg /dl;
- Hepatic dysfunction;
- History of malignant hyperthermia;
- Allergy to neuromuscular blocking drugs, Sugammadex, neostigmine or glycopyrrolate;
- Perioperative respiratory infections and/or pneumonia;
- Intubated or unresponsive;
- Pregnancy or breastfeeding.
Key Trial Info
Start Date :
November 14 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2021
Estimated Enrollment :
69 Patients enrolled
Trial Details
Trial ID
NCT03322657
Start Date
November 14 2017
End Date
February 1 2021
Last Update
November 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cleveland Clinic
Cleveland, Ohio, United States, 44195